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Abstract. Whole parasite immunization strategies employing genetically attenuated parasites (GAP), which arrest dur-
ing liver-stage development, have been applied successfully for induction of sterile malaria protection in rodents. Recently,
we generated a Plasmodium berghei GAP-lacking expression of multidrug resistance-associated protein (MRP2) (PbΔmrp2)
that was capable of partial schizogony in hepatocytes but showed complete growth arrest. Here, we investigated the protec-
tive efficacy after intravenous (IV) immunization of BALB/c and C57BL/6J mice with PbΔmrp2 sporozoites. Low-dose
immunization using 400 PbΔmrp2 sporozoites induced 100% sterile protection in BALB/c mice after IV challenge with
10,000 wild-type sporozoites. In addition, almost full protection (90%) was obtained after three immunizations with
10,000 sporozoites in C57BL/6J mice. Parasite liver loads in nonprotected PbΔmrp2-challenged C57BL/6J mice were reduced
by 86% ± 5% on average compared with naive control mice. The mid-to-late arresting PbΔmrp2 GAP was equipotent
in induction of protective immunity to the early arresting PbΔb9Δslarp GAP. The combined data support a clear basis
for further exploration of Plasmodium falciparum parasites lacking mrp2 as a suitable GAP vaccine candidate.
INTRODUCTION
Plasmodium berghei genetically attenuated parasite (GAP)
immunization strategies using whole, live parasites have been
applied successfully for induction of sterile malaria protection
in mice.1–3 Compared with immunizations using radiation-
attenuated parasites4 or sporozoites under chloroquine cover,5
GAPs have the advantages of consisting of homogenous
populations of attenuated parasites, and circumvent the neces-
sity of prophylactic drug use. This potentiates their use as a
vaccine strategy to prevent malaria, which is a severe disease
causing more than 400,000 deaths of (mostly) children under
5 years of age, annually.6 Multiple rodent GAPs have been
generated that abort development in the liver at different
time -points after invasion of hepatocytes resulting in different
levels of protection.7,8 By comparing two Plasmodium yoelii
GAPs, it was found that the late arresting P. yoelii PyΔfabb/f
GAP9 resulted in enhanced protective immunity as com-
pared with the early arresting PyΔsap110,11 highlighting the
potential benefit that late-arresting GAPs provide. Next to
inducing high-level protection, a critical requirement for a
vaccine consisting of GAP is complete attenuation of the
sporozoites and, hence, the absence of breakthrough blood-
stage infections after immunization.12 In contrast to the late-
arresting PyΔfabb/f GAP, immunization of mice with the
orthologous P. berghei Δfabb/f GAP resulted in break-
through blood infection in a number of mice, emphasizing
the need to generate fully attenuated GAPs. Recently, early
arresting P. berghei GAPs have been generated by removing
genes encoding sporozoite and liver asparagine-rich protein
(SLARP)13 (ortholog of P. yoelii SAP1) or B9.14 Immuniza-
tion of mice with mutant sporozoites lacking B9 mutant
resulted in low-grade blood-stage breakthrough infections.14
However, using a double gene deletion mutant lacking both
the b9 and the slarp gene (Δb9Δslarp), a complete arrest
was obtained at early liver stage with absence of both nuclear
division of parasites and exported protein 1 expression, a
marker for the parasitophorous vacuole membrane (PVM).15
High protective efficacy was obtained after immunization
of C57BL/6J mice with an immunization scheme of 3 ×
10,000 PbΔb9Δslarp sporozoites.15 More recently, we gen-
erated P. berghei mutants lacking expression of the adeno-
sine triphosphate–binding cassette transport protein MRP2
(Δmrp2) that showed a severely compromised phenotype
during liver-stage development resulting in complete arrest
at mid-to-late liver stage.16 Although PbΔmrp2 liver-stage
parasites show nuclear division and are still present at
52 hours postinfection, breakthrough blood infections were
never observed, even after administration of very high doses
of sporozoites.16 Here, our main objective was to address the
protective efficacy induced by immunization with PbΔmrp2
sporozoites in two different mouse strains, BALB/c and
C57BL/6J. Furthermore, we compared the induced protec-
tion to early arresting PbΔb9Δslarp GAP immunizations
performed in parallel.
METHODS
Experimental mice and P. berghei lines. Animal experi-
ments were performed in female C57BL/6J mice (from
8 weeks; Janvier, Le Genest-Saint-Isle, France) and approved
by the Radboud University Experimental Animal Ethical
Committee (RUDEC 2014-170). In animal experiments per-
formed at the Leiden University Medical Center, female
BALB/c (4–6 weeks old) from Charles River were used, as
approved by the Animal Experiments Committee of the
Leiden University Medical Center (DEC 12111). The Dutch
Experiments on Animal Act is established under European
guidelines on protection of animals used for scientific pur-
poses (EU directive no. 2010/63/EU). Two previously gener-
ated P. berghei ANKA mutant parasite lines were used to
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immunize mice: PbΔb9Δslarp (1844 cl1)15 and PbΔmrp2
(1025 cl2).16 For challenge of the immunized mice with wild-
type (WT) parasites, we used the reference P. berghei ANKA
line 676m1cl1 (PbGFP-Luccon)
17 that expresses the reporter
fusion protein green fluorescent protein (GFP)-luciferase.
Immunizations and challenge. Sporozoites of the three
above mentioned P. berghei lines were produced by feed-
ing infected mice to Anopheles stephensi mosquitoes.
After 3–4 weeks of parasite development, mosquitoes were
hand dissected, and salivary glands were homogenized in
Dulbecco’s Modified Eagle Medium (+4.5 g/L D-glucose,
+NEAA, -L-glutamine, -pyruvate; Life Technologies, Bleiswijk,
The Netherlands) supplemented with 1% human albumin
(Albuman; Sanquin, Nijmegen, The Netherlands) using a
homemade glass grinder. Sporozoites were then quantified
using a Bürker-Türk counting chamber using phase contrast
microscopy to prepare immunization or challenge solutions.
After anesthetizing using isoflurane, female BALB/c and
C57BL/6J mice were immunized and challenged by intrave-
nous (IV) injection of 200 μL sporozoite solution in the tail
vein according to the schedule presented in Figure 1A and
B. Thirty-one BALB/c mice were divided into groups of 16
and 15, receiving either PbΔb9Δslarp or PbΔmrp2 immuni-
zations. These groups were subdivided in three groups of
five (six in the high PbΔb9Δslarp dose group) mice receiving
immunization doses of 1 × 400, 1 × 800, or 1 × 1,200 sporozo-
ites. Immunized mice and five age-matched naive mice were
challenged after 21 days by 10,000 wild type PbGFP-Luccon
sporozoites, which express the GFP-luciferase reporter pro-
tein. For the C57BL/6J strain, 60 mice were divided into two
equal groups, receiving either PbΔb9Δslarp or PbΔmrp2
immunizations. These groups were subdivided in three groups
of 10 mice receiving immunization doses of 3 × 10,000, 3 ×
1,000, or 3 × 200 sporozoites with a 1-week interval between
each immunization. Immunized mice and three age-matched
naive mice were challenged after 14 days by 10,000 wild type
PbGFP-Luccon sporozoites. Subsequently, liver loads were
determined by measuring luciferase activity by biolumines-
cence imaging (see section In vivo liver-stage bioluminescence
imaging) 48 hours after injection of sporozoites, and tail blood
was analyzed by Giemsa-stained films for blood-stage posi-
tivity from 5 to 21 days post challenge.
In vivo liver-stage bioluminescence imaging. Forty-eight
hours after challenge with PbGFP-Luccon parasites, the para-
site liver load was determined in abdomen-shaved mice by
measuring luciferase activity by real-time in vivo imaging
using the IVIS Lumina II system (Caliper Life Sciences,
Hopkinton, MA) as described previously18,19 with minor
adaptations. In brief, BALB/c mice were injected subcutane-
ously in the neck with 60 μL (C57BL/6J: 200 μL) D-luciferin
(120 mg/kg [C57BL/6J: 150 mg/kg]; PerkinElmer, Groningen,
The Netherlands) dissolved in PBS (Life Technologies,
FIGURE 1. Schematic setup of mouse immunizations, challenge, and follow-up. (A) Thirty-one BALB/c mice were separated in groups of five
(and one group of six), and (B) 60 C57BL/6J mice were separated in groups of 10, receiving either PbΔb9Δslarp or PbΔmrp2 genetically attenu-
ated parasites immunization doses (BALB/c high: 1 × 1,200, medium: 1 × 800, low: 1 × 400 sporozoites; C57BL/6J high: 3 × 10,000, medium: 3 ×
1,000, low: 3 × 200 sporozoites) on the indicated days. All immunized mice and five (BALB/c) or three (C57BL/6J) naive controls were chal-
lenged with 10,000 WT sporozoites 2 weeks succeeding the last immunization. Liver-stage parasite development was monitored by biolumines-
cence (Biolum.) 2 days after challenge. Finally, tail smears were prepared to screen for malaria blood-stage positivity from daum 5 to 20 (BALB/c)
or 21 (C57BL/6J) (with varying intervals) after challenge.
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Gibco) 3 minutes (C57BL/6J: 4 minutes) before imaging.
After anesthetization by isoflurane, mice were imaged using
a field of view of 12.5 cm, medium binning factor and an
exposure time of 25–120 seconds (C57BL/6J: 300 sec.).
Luminescence intensity was quantified and visualized using
the Living Image 4.5 software (Caliper Life Sciences), shown
as rainbow plots with automatic scale bars per measure-
ment and represented as radiance units (photons/second/cm2/
steradian). The region of interest (ROI) was set to include the
liver, quantified the total flux of photons (photons/second) per
mouse and per dose group and is represented as the mean ±
standard error of the mean (SEM).
Statistical analysis. The different immunization groups were
scored on a binominal distribution (protected, blood smear
negative 20 or 21 days post challenge, or nonprotected,
blood smear positive) and significant differences between
these groups were determined using the Fisher’s exact test.
The ROIs of these immunization groups and naive controls,
calculated by the Living Image 4.5 software, were statisti-
cally compared with a one-way analysis of variance using
the Tukey’s posttest, and the overall percent reduction in
C57BL/6J liver load was depicted as mean (%) ± SEM. All
tests were performed using GraphPad Prism version 5.03
(GraphPad Software, San Diego, CA).
RESULTS AND DISCUSSION
To study the protective efficacy induced by immuniza-
tion of mice with sporozoites of the mid-to-late arresting
PbΔmrp2 GAP,16 we followed an immunization scheme
employing single doses of 1,200 (high), 800 (medium), or
400 (low) sporozoites in BALB/c mice followed by a chal-
lenge after 3 weeks (Figure 1A). Immunized mice were chal-
lenged with 10,000 GFP-luciferase expressing WT sporozoites
showing sterile protection in all mice immunized with the low
(5/5) and high dose (5/5), whereas three of five mice were
protected with the medium dose (Supplemental Figure 1).
Immunization of BALB/c mice with sporozoites of the early
arrester PbΔb9Δslarp induced a similar level of protection
(Supplemental Figure 1), as all mice immunized with the low
(5/5) and high (6/6) doses were protected against a subse-
quent challenge, whereas four of five mice were protected
with the medium dose. As expected, challenging naive BALB/c
mice with 10,000 WT sporozoites resulted in all five mice
becoming liver- and blood-stage positive (Supplemental
Figure 1). As summarized in Table 1, there was no significant
difference in protective efficacy induced by immunization of
BALB/c mice with PbΔb9Δslarp or PbΔmrp2 sporozoites.
Next, we immunized C57BL/6J mice, known as a more
stringent model for inducing protective immunity against
P. berghei,20 according to the scheme shown in Figure 1B.
Here, three weekly immunizations of 10,000 (high), 1,000
(medium), or 200 (low) were followed by challenge with
10,000 GFP-luciferase expressing WT sporozoites 2 weeks
after the last immunization. Eight days after the last immu-
nization, before challenge, we analyzed tail blood for the
presence of possible breakthrough blood infections. Neither
immunization with PbΔmrp2 nor PbΔb9Δslarp GAP para-
sites caused breakthrough infections, confirming previously
reported complete attenuation of these parasites.15,16 Nine of
10 mice immunized with the high dose of PbΔmrp2 were
completely protected against a WT challenge (Supplemental
Figure 1), which was clearly superior to the medium- and
low-dose immunization groups where none of the mice were
protected (P < 0.0001) (Table 1). Previously, it had been
shown that after three weekly immunizations of 10,000 spo-
rozoites of the early arresting PbΔb9Δslarp, sterile protec-
tion was obtained against a WT challenge.15 Here, three
PbΔb9Δslarp GAP immunizations (Supplemental Figure 1)
also resulted in sterile protection when using the high
dose. Protection declined dose-dependently, resulting in 3/
10 protected mice in the medium dose group (versus 6/1015)
and 0/10 protected mice in the low-dose group. As summa-
rized in Table 1, the high dose provided significant better
protection than the medium- (P = 0.0031) and low-dose
groups (P < 0.0001). As expected, all three naive mice became
liver- and blood-stage positive after challenge with 10,000 WT
sporozoites (Supplemental Figure 1). Although most C57BL/
6J mice in the medium- and low-dose groups became blood
smear positive after immunization using both GAPs, parasite
liver loads in all immunized groups were strongly reduced
(P < 0.0001) compared with control mice (Figure 2). The
nonprotected mice had an average reduction in liver load of
86% ± 5% and 90% ± 2% upon immunization with
PbΔmrp2 and PbΔb9Δslarp, respectively, highlighting the
immune potency of both GAPs.
It has been suggested that GAPs arresting late during liver
stage provide superior protection presumably due to expres-
sion of additional parasite proteins during late liver-stage
development and formation of daughter merozoites by schi-
zogony.7,8,11 PbΔmrp2 parasites enter schizogony as shown
by nuclear division, and develop to an average size of ∼50%
compared with fully developed liver-stage schizonts of WT
parasites.16 In contrast, PbΔb9Δslarp abort development soon
after invasion of the hepatocytes. These parasites remain very
small, have a compromised PVM, and show no features of
schizogony.14 Apparently, this difference in degree of devel-
opment between the two GAPs is not sufficient to translate
into a difference in induction of protective immune responses.
PbΔmrp2 parasites do produce a PVM in contrast to
PbΔb9Δslarp parasites. As the PVM is considered to function
TABLE 1
Protection in BALB/c or C57BL/6J mice immunized with PbΔmrp2
or PbΔb9Δslarp sporozoites
Mouse strain Parasite line Immunization dose(s) (sporozoites)
No. protected/
no. challenged
BALB/c PbΔmrp2 1 × 1,200 5/5*
1 × 800 3/5†
1 × 400 5/5
PbΔb9Δslarp 1 × 1,200 6/6‡
1 × 800 4/5
1 × 400 5/5
Naive control – 0/5
C57BL/6 PbΔmrp2 3 × 10,000 9/10§
3 × 1,000 0/10‖
3 × 200 0/10
PbΔb9Δslarp 3 × 10,000 10/10¶**
3 × 1,000 3/10
3 × 200 0/10
Naive control – 0/3
*P = 0.44 (Fisher’s exact test) for PbΔmrp2 1 × 1,200 vs. 1 × 800.
†P = 1 (Fisher’s exact test) for PbΔmrp2 1 × 800 vs. PbΔb9Δslarp 1 × 800.
‡P = 0.45 (Fisher’s exact test) for PbΔb9Δslarp 1 × 1,200 vs. 1 × 800.
§P = 0.0001 (Fisher’s exact test) for PbΔmrp2 3 × 10,000 vs. 3 × 1,000 or 3 × 200.
‖P = 0.21 (Fisher’s exact test) for PbΔmrp2 3 × 1,000 vs. PbΔb9Δslarp 3 × 1,000.
¶P = 0.0031 (Fisher’s exact test) for PbΔb9Δslarp 3 × 10,000 vs. 3 × 1,000.
**P < 0.0001 (Fisher’s exact test) for PbΔb9Δslarp 3 × 10,000 vs. 3 × 200.
380 VAN DER VELDEN, RIJPMA AND OTHERS
as decoy for host defense mechanisms including autophagy,21
it is possible that PbΔb9Δslarp parasites might be more prone
to intracellular degradation, resulting in relatively effective
antigen presentation. This might explain why PbΔb9Δslarp
parasites, despite expressing fewer antigens, induce compa-
rable protective immune responses as PbΔmrp2 parasites.
While the late arresting P. yoelii Δfabb/f GAP9 forms a PVM
and lacks expression of MSP1, a similar phenotype as com-
pared with the mid-to-late arresting P. berghei Δmrp2 GAP,16
the PyΔfabb/f GAP induces stronger protective immune
responses compared with the early arresting PyΔsap1 GAP.11
Whether this is caused by parasite species (P. yoelii versus
P. berghei) or difference in antigen presentation between the
PyΔfabb/f GAP and the PbΔmrp2 GAP remains to be inves-
tigated in comparable immunization/challenge protocols.
While potency is important, it is absolutely essential that
GAP immunizations will be safe and do not result in break-
through blood infections. Several P. berghei GAPs do gen-
erate protective immunity, but most produce breakthrough
blood infections at high doses.12 The only safe P. berghei
GAPs based on single gene deletions are slarp10,13,15 or
mrp2 gene knock-out parasites.16 As we have reported here,
both studied GAPs are capable of generating highly potent
protective immunity in different strains of mice. To further
reduce the risks for breakthrough infections, it has been
recommended to delete multiple genes targeting vital but
independent functions during liver-stage development.22 Cur-
rently, two multiple gene deletion GAPs have been gener-
ated in P. falciparum, and in both lines the slarp gene has
been removed.15,23 These early arresting P. falciparum GAPs
have undergone preclinical evaluation for safety and are
now being advanced into Phase 1 clinical trials.15,23,24 Com-
bining PfΔslarp with PfΔmrp2, active in unrelated pathways,
would remove two genes both of which independently result
in complete liver-stage arrest (increases the safety profile of
the GAP). Moreover, as PbΔmrp2 is the first mid-to-late
arresting GAP that shows both protective efficacy and no
evidence for breakthrough blood infections, we believe that
P. falciparum GAPs lacking the mrp2 gene merit investiga-
tion to further develop a GAP vaccine that is suitable and
potent for human use.
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